The impact of firstline immunotherapy and tyrosine kinase inhibitors combinations versus sunitinib on clinical outcomes of favorable risk advanced renal cell carcinoma: A meta-analysis of randomized studies.

Authors: Ankita Gupta, Jamie Lee Aldakkour, Sireesha Vutukuri, Philip A. Haddad

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16504

Source: Full article

e16504